logo
How social media can 'trigger' eating disorders in young people

How social media can 'trigger' eating disorders in young people

Yahoo2 days ago

Social media can push vulnerable young people towards developing eating disorders by glorifying thinness and promoting fake, dangerous advice about diet and nutrition, experts warn.
Young women and girls are much more likely to suffer from illnesses such as anorexia, bulimia and binge eating disorder, though rates among men have been increasing.
Research has shown the percentage of people worldwide who have had some kind of eating disorder during their lives rose from 3.5 percent in 2000 to 7.8 percent in 2018, a timeframe that captures the rise of social media.
For the professionals trying to help teenagers recover from these disorders, misinformation from influencers on platforms such as TikTok and Instagram is a huge problem.
"We no longer treat an eating disorder without also addressing social media use," French dietitian and nutritionist Carole Copti told AFP.
"It has become a trigger, definitely an accelerator and an obstacle to recovery," she added.
The causes of eating disorders are complex, with psychological, genetic, environmental and social factors all having the potential to make someone more susceptible.
Social media "is not the cause but the straw that may break the camel's back," said Nathalie Godart, a psychiatrist for children and adolescents at the Student Health Foundation of France.
By promoting thinness, strictly controlled diets and relentless exercise, social media weakens already vulnerable people and "amplifies the threat" to their health, she told AFP.
- 'Vicious cycle' -
Just one recent example is the #skinnytok trend, a hashtag on TikTok full of dangerous and guilt-inducing advice encouraging people to drastically reduce how much food they eat.
For Charlyne Buigues, a French nurse specialising in eating disorders, social media serves as a gateway to these problems, which are "normalised" online.
She condemned videos showing young girls with anorexia exposing their malnourished bodies -- or others with bulimia demonstrating their "purges".
"Taking laxatives or vomiting are presented as a perfectly legitimate way to lose weight, when actually they increase the risk of cardiac arrest," Buigues said.
Eating disorders can damage the heart, cause infertility and other health problems, and have been linked to suicidal behaviour.
Anorexia has the highest rate of death of any psychiatric disease, research has found. Eating disorders are also the second leading cause of premature death among 15- to 24-year-olds in France, according to the country's health insurance agency.
Social media creates a "vicious cycle," Copti said.
"People suffering from eating disorders often have low self-esteem. But by exposing their thinness from having anorexia on social media, they gain followers, views, likes... and this will perpetuate their problems and prolong their denial," she added.
This can especially be the case when the content earns money.
Buigues spoke of a young woman who regularly records herself throwing up live on TikTok and who had "explained that she was paid by the platform and uses that money to buy groceries".
- 'Completely indoctrinated' -
Social media also makes recovering from eating disorders "more difficult, more complicated and take longer", Copti said.
This is partly because young people tend to believe the misleading or fake diet advice that proliferates online.
Copti said consultations with her patients can feel like she is facing a trial.
"I have to constantly justify myself and fight to make them understand that no, it is not possible to have a healthy diet eating only 1,000 calories -- that is half what they need -- or that no, it is not normal to skip meals," she said.
"The patients are completely indoctrinated -- and my 45-minute weekly consultation is no match for spending hours every day on TikTok," she added.
Godart warned about the rise of people posing as "pseudo-coaches", sharing incorrect, "absurd" and potentially illegal nutrition advice.
"These influencers carry far more weight than institutions. We're constantly struggling to get simple messages across about nutrition," she said, pointing out that there are lifelines available for those in need.
Buigues takes it upon herself to regularly report problematic content on Instagram, but said it "serves no purpose".
"The content remains online and the accounts are rarely suspended -- it's very tiring," she said.
The nurse has even advised her patients to delete their social media accounts, particularly TikTok.
"It may seem radical but until young people are better informed, the app is too dangerous," she said.
cra-dl/djt

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU climate investments lagging 'well below' target
EU climate investments lagging 'well below' target

News24

timean hour ago

  • News24

EU climate investments lagging 'well below' target

Climate investments in the EU are still far below what is needed to transition away from fossil fuels, a new report warned. Between 2022 and 2023, EU-wide investments grew from 491 to 498 billion euros (~R9.9-R10 trillion) - with the data available so far for 2024 pointing to a slowdown. The EU has set a goal of becoming carbon neutral by 2050, and says it has already cut emissions by 37% compared to 1990. For climate change news and analysis, go to News24 Climate Future. Climate investments in the 27-nation EU are still far below what is needed to transition away from fossil fuels, a new report warned Tuesday, spotlighting lagging investments in wind power and building renovation. After a stretch of sustained growth, public and private investments in key climate-related sectors - energy, buildings, transport and clean-tech manufacturing - have been flatlining in recent years, said the report by the Institute for Climate Economics (I4CE). Between 2022 and 2023, EU-wide investments grew from 491 to 498 billion euros (~R9.9-R10 trillion) - with the data available so far for 2024 pointing to a slowdown, the think tank found. Present investment levels were "well below" what the bloc needs to meet its 2030 emissions reduction goal, which the institute estimates to require 842 billion euros (~R15 trillion) each year. The findings contrast with the signal sent by the European Commission, which last week declared the bloc on track to meet its 2030 target of slashing planet-warming emissions by 55 % compared to 1990 levels. The commission's upbeat projection was based on the energy and climate plans drawn up by EU member states. "It's easy to set goals, more difficult to implement the policies," cautioned Jean Pisani-Ferry, the I4CE's chair, at the report's launch in Brussels. Wind power and energy renovations in older buildings are falling especially short - with investments at around one third of what is needed, the report said. Solar power investments, however, were on the right track. The I4CE did not factor in investments in nuclear power, which it says remain outside the scope of its report because "the EU does not have precise objectives to develop nuclear energy." The EU's vice president for the clean transition, Teresa Ribera - who was present for the report's launch - acknowledged the investment shortfall was a "point of concern". "We can do better," she said, arguing that "a lot of strengths are not fully exploited" within the bloc. The EU has set a goal of becoming carbon neutral by 2050, and says it has already cut emissions by 37% compared to 1990. Brussels now needs to agree on an interim target for 2040 - expected to be unveiled on 2 July - with the commission seeking to cut emissions by 90% compared to 1990 levels.

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Associated Press

time2 hours ago

  • Associated Press

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion. Alyssa Johnsen, MD, PhD Global Therapeutic Area Head, Immunology and Oncology Development 'Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation thatcouldimprove and streamline the treatment process for both patients and providers. We are pleased to share thesedata, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forwardtopotentiallybringing this formulation and administrationoptionto the multiple myeloma community.' The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection. The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections' enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort. The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any regulatory authority. IRAKLIA phase 3 study IRAKLIA is a global, randomized, open-label, pivotal phase 3 non-inferiority study comparing Sarclisa SC administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone (Pd) in adult patients with R/R MM who have received at least one prior line of treatment. At the data cut-off of November 6, 2024, and a median follow-up of 12 months, the study demonstrated: Primary endpoints Secondary endpoints The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a notably lower rate of systemic IRs. No new safety concerns were observed, except for low-grade local injection site reactions (ISRs) associated with SC administration that occurred with a low incidence (0.4%, n=19/5,145 injections). Nearly all ISRs were grade 1, except for one episode of grade 2. Xavier Leleu, MD, PhD Head of the Department of Hematology and Myeloma Clinic at the Hôpital La Mileterie and study investigator 'Results from the IRAKLIA phase 3 study represent a potentially transformational advancement in the administration of multiple myeloma treatment. These data not only establish non-inferiority between Sarclisa administered both subcutaneously and intravenously across several key endpoints but reinforce the positive impact that this on-body injector could have on the patient treatment experience, as demonstrated by patient satisfaction scores.' In addition to the oral presentation at ASCO, the full data were simultaneously published in the Journal of Clinical Oncology. IZALCO phase 2 study In addition to the IRAKLIA phase 3 study, Sanofi also presented new data from the randomized, sequential, open-label, IZALCO phase 2 study evaluating the efficacy and safety of Sarclisa SC administered via manual push or an OBI, in combination with carfilzomib and dexamethasone (Kd) in adult patients with R/R MM who have received one to three prior lines of therapy. At a median follow-up of 10.1 months, the study demonstrated: The overall safety profile of Sarclisa SC-Kd observed in this study was consistent with the established safety profile of Sarclisa IV-Kd, with no new safety concerns observed. Advancing patient and provider-centric innovation in MM While SC administration is currently available for certain MM treatment regimens through a manual injection, administering large-volume medicines manually can present significant challenges, including a labor-intensive process for nurses, risk of strain and needlestick injuries, and potential need for larger needles that may compromise patient comfort and increase anxiety. Mehul Desai, PharmD, MBA Vice President, Medical Affairs, Enable Injections 'We believe multiple myeloma patients deserve a more convenient and comfortable treatment experience and recognize the crucial role providers play in delivering that care. Through our collaboration with Sanofi, we've aspired to advance an on-body injector that could transform the treatment experience for patients and providers alike. The results from the IRAKLIA and IZALCO studies represent a significant step toward our ambition and validate the potential of the on-body injector to deliver the same high standard of efficacy established with intravenous Sarclisa.' In addition to IRAKLIA and IZALCO, Sanofi is also evaluating Sarclisa SC administration via an OBI in the front-line treatment setting. The ISASOCUT phase 2 study conducted by the University of Poitiers, is evaluating Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) in adult patients with newly diagnosed MM (NDMM) not eligible for autologous stem-cell transplant (ASCT), while the German-speaking Myeloma Multicenter Group (GMMG)-HD8 phase 3 study, conducted in collaboration with the GMMG and the German Multiple Myeloma Study Group Consortium (DSMM), is evaluating Sarclisa SC-VRd induction in NDMM patients who are eligible for ASCT. In addition, results from the IZALCO, IRAKLIA and ISASOCUT studies will be presented at the European Hematology Association Congress later this month. The IRAKLIA abstract was also hand-selected to be included in the 2025 Best of ASCO program, held later in the summer of 2025, following the ASCO Annual Meeting. The data from these studies, collectively, will form the basis for global regulatory submissions. Sarclisa administered subcutaneously via the on-body injector or manual administration is investigational and has not been approved for any use by any regulatory authority. The safety and efficacy of this formulation and delivery method have not been established. About the IRAKLIA and IZALCO studies IRAKLIA is a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of Sarclisa SC formulation administered at a fixed dose SC via an OBI versus weight-based dosed Sarclisa IV in combination with Pd in adult patients with R/R MM who have received at least one prior line of therapy. The co-primary outcomes being assessed are ORR, defined as the proportion of patients with stringent CR, CR, VGPR, and partial response (PR) according to the 2016 IMWG criteria assessed by Independent Review Committee (IRC), and observed C trough at steady state (pre-dose at C6D1), defined as observed Sarclisa plasma concentrations. IZALCO is a two-part, randomized, sequential, open-label, phase 2 study evaluating the efficacy and safety of Sarclisa SC formulation administered SC via manual push or an OBI in adult patients with R/R MM who have received one to three prior lines of therapy. The primary objective is ORR, as assessed by IRC. The secondary objective is patient preference for the OBI versus manual administration of Sarclisa SC. About Enable Injections Based in the US (Cincinnati, OH), Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse. enFuse is an innovative wearable drug delivery platform that is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit About Sarclisa Sarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, UK, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media Relations Sandrine Guendoul | +33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Léo Le Bourhis | +33 6 75 06 43 81 | [email protected] Victor Rouault | +33 6 70 93 71 40 | [email protected] Timothy Gilbert | +1 516 521 2929 | [email protected] Investor Relations Thomas Kudsk Larsen |+44 7545 513 693 | [email protected] Alizé Kaisserian | +33 6 47 04 12 11 | [email protected] Felix Lauscher | +1 908 612 7239 | [email protected] Keita Browne | +1 781 249 1766 | [email protected] Nathalie Pham | +33 7 85 93 30 17 | [email protected] Tarik Elgoutni | +1 617 710 3587 | [email protected] Thibaud Châtelet | +33 6 80 80 89 90 | [email protected] Yun Li | +33 6 84 00 90 72 | [email protected] Sanofi forward-looking statements All trademarks mentioned in this press release are the property of the Sanofi group with the exception of enFuse. Attachment

Effects of BMI and Socioeconomic Status on GWG
Effects of BMI and Socioeconomic Status on GWG

Medscape

time3 hours ago

  • Medscape

Effects of BMI and Socioeconomic Status on GWG

Body mass index (BMI), socioeconomic position, and mental health were key determinants of unhealthy gestational weight gain (GWG) among UK women. METHODOLOGY: Researchers performed a secondary analysis of the Born in Bradford cohort to evaluate determinants of unhealthy GWG among UK women. They included 7769 singleton pregnancies and live, term births (≥ 37 to ≤ 42 weeks' gestation). Maternal weight was measured at the first antenatal appointment (median, 11 weeks), study recruitment (~26-28 weeks' gestation; height also recorded), and third trimester (median, 36 weeks); baseline BMI was assessed, and mental health was assessed using the General Health Questionnaire-28. GWG was categorised as less than the recommended weight gain (RWG), RWG, and more than the RWG on the basis of the Institute of Medicine (IOM) 2009 criteria for weekly average weight gain. TAKEAWAY: Only 22.4% of women achieved the recommended GWG; 20.3% gained less and 57.3% gained more than the recommended GWG. Compared with women with a healthy baseline BMI, women with underweight (adjusted odds ratio [aOR], 1.78; P < .001), overweight (aOR, 1.37; P < .001), and obesity (aOR, 1.30; P = .014) had higher odds of gaining less weight than the RWG. < .001), overweight (aOR, 1.37; < .001), and obesity (aOR, 1.30; = .014) had higher odds of gaining less weight than the RWG. Women in the "benefits but coping" socioeconomic class (aOR, 1.42; P = .002) and those in the "most deprived" category (aOR, 1.37; P = .014) had higher odds of having GWG below the RWG. = .002) and those in the "most deprived" category (aOR, 1.37; = .014) had higher odds of having GWG below the RWG. Women with underweight had lower odds of experiencing GWG above the RWG (aOR, 0.58; P < .001), whereas those with overweight (aOR, 3.56) and obesity (OR, 5.86; P < .001 for both) had dramatically higher odds. Pregnancies with a high risk for psychiatric morbidity were linked to increased odds of having GWG above the RWG (aOR, 1.22; P = .003). IN PRACTICE: "Our results may help inform organisations on which groups of women are at greater risk of unhealthy weight gain during pregnancy, such as those with mental health issues, unhealthy baseline BMI, and/or facing economic deprivation," the authors wrote. SOURCE: This study was led by Petra A.T. Araujo, National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England. It was published online on May 23, 2025, in PLOS One . LIMITATIONS: Obtaining accurate GWG measurements posed challenges due to the varying timing of measurements and lack of universal pre-pregnancy weight data. The IOM-recommended criteria might not be optimal for non-US populations and do not initially account for ethnic differences. The study cohort lacked data on late third trimester weight, restricting the ability to assess the absolute GWG. DISCLOSURES: This study was supported by an Intermediate Research Fellowship from the Nuffield Department of Population Health at the University of Oxford, United Kingdom. The authors declared having no competing interests.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store